Leading medical experts in bone metastases and prostate cancer therapy to present at Algeta Capital Markets Days
(Thomson Reuters ONE) -
Oslo - 25 May 2010
London - 27 May 2010
Oslo, Norway, 26 April 2010 - Algeta ASA (OSE: ALGETA), the focused oncology
company, has the pleasure of inviting members of the financial community and
press to its Capital Markets Days in Oslo on Tuesday 25 May and in London, UK on
Thursday 27 May 2010.
The meetings will provide an opportunity to hear from leading medical experts in
the field of bone metastases and prostate cancer therapy, both of whom are
currently involved in the Company's phase III ALSYMPCA trial, and who will
provide valuable clinical insights into their specialist field.
ALSYMPCA (Alpharadin in symptomatic prostate cancer patients) is a global phase
III clinical trial evaluating the potential of Alpharadin (radium-223 chloride)
to treat bone metastases resulting from hormone-refractory
(castration-resistant) prostate cancer (HRPC). Alpharadin is partnered with
Bayer Schering Pharma AG.
* At the Oslo meeting, the key speaker will be Professor Sten Nilsson, Head of
the Urologic Oncology Group at the Karolinska Hospital and Institute in
Stockholm, Sweden. Prof. Nilsson was the Principal Investigator of Algeta's
phase II BC1-02 clinical trial with Alpharadin.
* At the London meeting, the key speaker will be Dr Chris Parker from the
Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK. Dr
Parker is the Principal Investigator of Algeta's phase III ALSYMPCA clinical
trial.
In addition to these expert speakers, attendees will gain an in-depth
understanding from Algeta's senior management team about the Company, its lead
product Alpharadin as a potential new treatment for bone metastases in cancer
patients, plans for the commercial manufacturing facility and the opportunities
presented by thorium alpha-pharmaceuticals to form the basis of a pipeline of
new targeted cancer therapeutics.
Preliminary programs are attached.
Details of the events and how to register are as follows:
Tuesday 25 May, 2010 Thursday 27 May, 2010
Oslo, Norway London, UK
08.00 - 11.00am (CET) including breakfast 13.30 - 16.15pm (BST) followed by
and followed by lunch drinks and canapés
Hotel Continental Citigate Dewe Rogerson
Stortingsgaten 24/26 3 London Wall Buildings
0117 Oslo London EC2M 5SY
Norway UK
To register, please contact: To register, please contact:
Renate Birkeli (Algeta) Mark Swallow (Citigate Dewe Rogerson)
post(at)algeta.com
+47 2300 7990
+44 207 282 2948
For further information, please contact
Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)
Øystein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob)
post(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow/Helena Galilee/David Dible mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
###
About Algeta
Algeta is a focused oncology company developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (based on radium-223) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting
side-effects.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g.
prostate, breast and lung.
Alpharadin is partnered with Bayer Schering Pharma AG, a major pharmaceutical
company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone
metastases resulting from hormone-refractory (castration-resistant) prostate
cancer. Alpharadin is also under investigation in phase II clinical trials as a
potential new treatment for bone metastases in endocrine-refractory breast
cancer patients.
Algeta also aims to develop a future pipeline of tumor-targeting
alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227,
through selective in-licensing and/or acquiring innovative technologies and
tumor-targeting molecules.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta
listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1407969]
Capital markets day - London: http://hugin.info/134655/R/1407969/360857.pdf
Press release: http://hugin.info/134655/R/1407969/360858.pdf
Capital markets day - Oslo: http://hugin.info/134655/R/1407969/360856.pdf
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2010 - 10:00 Uhr
Sprache: Deutsch
News-ID 19644
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Leading medical experts in bone metastases and prostate cancer therapy to present at Algeta Capital Markets Days"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
